Latest1 information on COVID-19
©2022 Stanford Medicine
Trial ID: NCT00238615
A Phase II Trial of Concurrent Docetaxel (Taxotere) / Carboplatin / Radiotherapy Followed by Surgical Resection Followed by Consolidation Taxotere / Carboplatin in Stage III Non-Small Cell Lung Cancer (NSCLC)
Professor of Medicine (Oncology)
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Professor of Radiation Oncology (Radiation Therapy)
Histologically confirmed stage IIIA or IIIB NSCLC
- Patients must have measurable disease
- No previous chemotherapy, radiation therapy or other systemic therapy for their NSCLC.
- Age>18 years
- Life expectancy >12 months
- ECOG performance status 0-1
- Normal organ and marrow function
- Medically fit for surgery at time of enrollment.
- Women of childbearing potential and men must agree to use adequate contraception prior
to study entry and for the duration of the study. Women must have a negative pregnancy
test prior to enrollment.
- Ability to understand and willingness to sign the consent form.
- Previous chemotherapy, radiation therapy or any other systemic treatment for their
- Patients receiving any other investigational agents.
- Known metastatic disease (brain or any other site)
- History of severe hypersensitivity reaction to docetaxel or other drugs formulated
with polysorbate 80 or with allergic reactions to compounds of similar chemical
composition to carboplatin or other agents used in the study.
- Peripheral neuropathy >grade 1
- Uncontrolled concurrent illness
- Pregnant women
- Weight loss>10% in the past 3 months before diagnosis.
- Hyperglycemia - exclusion from PET analysis
- HIV positive patients receiving combination anti-retroviral therapy because of
possible pharmacokinetic interactions with docetaxel and carboplatin or other agents
administered during the study.
procedure: Radiation therapy
procedure: Surgical resection
School of Medicine
300 Pasteur Drive
Stanford, CA 94305